Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.100 GeneticVariation disease BEFREE "Masculinity theory" was used to report the impact of having both a BRCA1/2 mutation and PCa. 28812325 2017
Entrez Id: 100505887
Gene Symbol: LINC01672
LINC01672
0.050 Biomarker disease BEFREE <b>Abbreviation used:</b> A549 (human lung carcinoma), Caco-2 (Human ColonCarcinoma), CHCl3 (Chloroform), HCT 116 (Human Colon Carcinoma), HepG2 (Liver Hepatocellular Carcinoma), HT-29 (Human Colorectal Adenocarcinoma), MCF-7 (Michigan Cancer Foundation-7; Human Breast Adenocarcinoma), MeOH (Methanol), NMR Nuclear Magnetic Resonance), PBS (Phosphate Buffered Saline), PC-3 (Human Prostate Cancer), PTLC (Preparative Thin Layer Chromatography), RPMI-1640 (Roswell Park Memorial Institute medium), TLC (ThinLayer Chromatography). 28479724 2017
Entrez Id: 3146
Gene Symbol: HMGB1
HMGB1
0.100 Biomarker disease BEFREE <b>Background and Aim</b>: We have previously shown that high-mobility group box 1 (<i>HMGB1</i>) is an independent biomarker for shortened survival of prostate cancer (PCa) patients. 31410208 2019
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker disease BEFREE <b>Background:</b> By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels. 28529650 2017
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.200 Biomarker disease BEFREE <b>Background:</b> By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels. 28529650 2017
Entrez Id: 29968
Gene Symbol: PSAT1
PSAT1
0.100 Biomarker disease BEFREE <b>Background:</b> By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels. 28529650 2017
Entrez Id: 9520
Gene Symbol: NPEPPS
NPEPPS
0.100 Biomarker disease BEFREE <b>Background:</b> By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels. 28529650 2017
Entrez Id: 5627
Gene Symbol: PROS1
PROS1
0.100 Biomarker disease BEFREE <b>Background:</b> By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels. 28529650 2017
Entrez Id: 5324
Gene Symbol: PLAG1
PLAG1
0.100 Biomarker disease BEFREE <b>Background:</b> By targeting the prostate-specific membrane antigen (PSMA) on prostate cancer (PCa) cells PSMA-PET/CT shows great potential in locating the site of biochemical recurrence even at low PSA (Prostate-specific antigen)-levels. 28529650 2017
Entrez Id: 354
Gene Symbol: KLK3
KLK3
0.200 Biomarker disease BEFREE <b>Background:</b> This study sought to ascertain whether there is an association between prostate cancer (PC)-specific mortality (PCSM) and timing of salvage androgen deprivation therapy (ADT) among men with short versus long prostate-specific antigen doubling times (PSA-DTs). 29891524 2018
Entrez Id: 55503
Gene Symbol: TRPV6
TRPV6
0.100 Biomarker disease BEFREE <b>Background:</b> Transient Receptor Potential Vanilloid 6 (TRPV6), a non-voltage gated calcium channel, is implicated in malignancies and correlates with Gleason scores in prostate cancer and with poor prognosis in breast cancer. 30210643 2018
Entrez Id: 6935
Gene Symbol: ZEB1
ZEB1
0.100 Biomarker disease BEFREE <b>Conclusion</b>: Our findings elucidated that copy number gains of ZEB1-triggered a TGF-β signaling-dependent miR-33a-5p-mediated negative feedback loop was highly relevant to the bone metastasis of PCa. 31534537 2019
Entrez Id: 1545
Gene Symbol: CYP1B1
CYP1B1
0.100 GeneticVariation disease BEFREE <b>Conclusion.</b> This meta-analysis revealed a clear association between rs1048943 and rs4646903 polymorphisms of the <i>CYP1A1</i> gene but not between CYP1B1 rs10012, rs162549, rs1800440, and rs2551188 polymorphisms and the risk of PCa. 30765615 2019
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker disease BEFREE <b>Conclusion:</b> PSMA-targeting probes with trifluoroborate prosthetic groups represent promising candidates for prostate cancer imaging because of facile labeling while affording high tumor uptake values and contrast ratios that are similar to those obtained with <sup>18</sup>F-DCFPyL. 30737299 2019
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker disease BEFREE <b>Conclusion:</b> In our analysis, preoperative 1-stop-shop <sup>68</sup>Ga-PSMA-11 PET/MRI performs at least equally for T and N stage prediction compared with nomograms in high-risk prostate cancer patients. 29794224 2018
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker disease BEFREE <b>Conclusion:</b> In this pilot study, <sup>18</sup>F-PSMA-1007 PET/CT presented high potential for localization of recurrent disease in prostate cancer patients with BCR. 29419475 2018
Entrez Id: 51386
Gene Symbol: EIF3L
EIF3L
0.010 Biomarker disease BEFREE <b>Conclusion:</b> In this study, we demonstrated that the regulation of eIF3L palmitoylation may provide new directions for the therapy of prostate cancer. 31239713 2019
Entrez Id: 1545
Gene Symbol: CYP1B1
CYP1B1
0.100 GeneticVariation disease BEFREE <b>CONCLUSION:</b> Our findings suggest that genetic variants within <i>CYP1B1</i> may confer genetic susceptibility to PCa by altering telomere length. 29344273 2018
Entrez Id: 6868
Gene Symbol: ADAM17
ADAM17
0.040 AlteredExpression disease BEFREE <b>Conclusion:</b> Overexpression of circHIPK3 promotes the proliferative and invasive potentials of PCa cells through sponging miRNA-338-3p to regulate ADAM17 expression, thus accelerating the malignant progression of PCa. 31118688 2019
Entrez Id: 6462
Gene Symbol: SHBG
SHBG
0.100 AlteredExpression disease BEFREE <b>Conclusion:</b> Prebinding of <sup>18</sup>F-FDHT to SHBG allows accurate and quantitative PET imaging of AR levels in murine models of prostate cancer. 29853654 2018
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 GeneticVariation disease BEFREE <b>Conclusion:</b> Synchronous <sup>68</sup>Ga-labeled prostate-specific membrane antigen-avid malignancies were rare (0.7%) in PC patients; atypical lesions were more commonly unusual PC metastases (1.0%) or benign (3.1%). 28572488 2017
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker disease BEFREE <b>Conclusion:</b> The combination of Lu-PSMA and SIRT is efficient and feasible for the treatment of advanced prostate cancer. 31601703 2019
Entrez Id: 407040
Gene Symbol: MIR34A
MIR34A
0.100 Biomarker disease BEFREE <b>Conclusion:</b> The DANCR/miR-34a-5p axis enhanced DTX resistance of PC via targeting JAG1, providing a novel insight to improve chemotherapy for PC. 31371987 2019
Entrez Id: 182
Gene Symbol: JAG1
JAG1
0.070 Biomarker disease BEFREE <b>Conclusion:</b> The DANCR/miR-34a-5p axis enhanced DTX resistance of PC via targeting JAG1, providing a novel insight to improve chemotherapy for PC. 31371987 2019
Entrez Id: 2346
Gene Symbol: FOLH1
FOLH1
0.100 Biomarker disease BEFREE <b>Conclusion:</b> The radiofluorinated PSMA ligand showed promising characteristics in its preclinical evaluation, and the feasibility of prostate cancer imaging was demonstrated by small-animal PET studies. 27789722 2017